Literature DB >> 15252882

[Folate against hyperhomocysteinemia. A new approach for the prevention and therapy of alcoholism-associated disorders?].

S Bleich1, K Löffelholz, J Kornhuber.   

Abstract

There is growing evidence that chronic alcoholism is associated with a derangement in the sulfur amino acid metabolism. Excitatory aminoacids such as glutamate, aspartate, and homocysteine have been shown to be increased in patients with chronic alcoholism who underwent alcohol withdrawal. Furthermore, sustained hyperhomocysteinemia occurred in chronic alcoholics with active drinking pattern. Excitotoxicity can be induced by increased hormocysteine levels via rebound activation of NMDA receptor-mediated glutamatergic neurotransmission upon the removal of ethanol-evoked inhibition. Therefore, hyperhomocysteinemia may be responsible for the higher incidence of complications during alcohol withdrawal (e.g.stroke,convulsions). In addition, an association between brain atrophy and increased levels of homocysteine in chronic alcoholism was shown. This may have important implications for the pathogenesis of brain atrophy in alcoholics. Taking into account that high plasma homocysteine levels are helpful in the prediction of alcohol withdrawal seizures, early anti-convulsive therapy could prevent this severe complication. Supplementation of folate, a cofactor of the homocysteine metabolism, lowers raised homocysteine levels and therefore could be established as a new therapeutic strategy in alcohol withdrawal treatment. The results of various studies highlight the need for further research to prove whether alcoholics benefit from a reduced homocysteine level with respect to both, alcohol-related disorders and alcohol withdrawal symptoms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15252882     DOI: 10.1007/s00115-003-1606-2

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  45 in total

Review 1.  Homocysteine metabolism.

Authors:  J Selhub
Journal:  Annu Rev Nutr       Date:  1999       Impact factor: 11.848

2.  Memantine in moderate-to-severe Alzheimer's disease.

Authors:  Stefan Bleich; Jens Wiltfang; Johannes Kornhuber
Journal:  N Engl J Med       Date:  2003-08-07       Impact factor: 91.245

3.  Effects of chronic ethanol treatment on the expression of calcium transport carriers and NMDA/glutamate receptor proteins in brain synaptic membranes.

Authors:  X Chen; M L Michaelis; E K Michaelis
Journal:  J Neurochem       Date:  1997-10       Impact factor: 5.372

4.  The effect of folic acid fortification on plasma folate and total homocysteine concentrations.

Authors:  P F Jacques; J Selhub; A G Bostom; P W Wilson; I H Rosenberg
Journal:  N Engl J Med       Date:  1999-05-13       Impact factor: 91.245

Review 5.  Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence.

Authors:  J W Eikelboom; E Lonn; J Genest; G Hankey; S Yusuf
Journal:  Ann Intern Med       Date:  1999-09-07       Impact factor: 25.391

6.  Oxidative stress and an altered methionine metabolism in alcoholism.

Authors:  S Bleich; K Spilker; C Kurth; D Degner; M Quintela-Schneider; K Javaheripour; E Rüther; J Kornhuber; J Wiltfang
Journal:  Neurosci Lett       Date:  2000-11-03       Impact factor: 3.046

7.  Hyperhomocysteinemia as a new risk factor for brain shrinkage in patients with alcoholism.

Authors:  S Bleich; B Bandelow; K Javaheripour; A Müller; D Degner; J Wilhelm; U Havemann-Reinecke; W Sperling; E Rüther; J Kornhuber
Journal:  Neurosci Lett       Date:  2003-01-02       Impact factor: 3.046

Review 8.  Mechanisms of excitotoxicity in neurologic diseases.

Authors:  M F Beal
Journal:  FASEB J       Date:  1992-12       Impact factor: 5.191

9.  PATHOLOGICAL FINDINGS IN HOMOCYSTINURIA.

Authors:  J B GIBSON; N A CARSON; D W NEILL
Journal:  J Clin Pathol       Date:  1964-07       Impact factor: 3.411

10.  Homocysteinemia due to folate deficiency.

Authors:  S S Kang; P W Wong; M Norusis
Journal:  Metabolism       Date:  1987-05       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.